Entera Bio (NASDAQ:ENTX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Entera Bio (NASDAQ:ENTX) announced its quarterly earnings data on Friday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05), FiscalAI reports.

Entera Bio Stock Performance

ENTX traded up $0.15 during mid-day trading on Friday, reaching $3.14. 117,978 shares of the stock were exchanged, compared to its average volume of 598,459. Entera Bio has a 1 year low of $0.91 and a 1 year high of $4.20. The stock has a market capitalization of $546.11 million, a PE ratio of -8.97 and a beta of 1.48. The company has a 50 day moving average price of $2.88 and a two-hundred day moving average price of $1.95.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ENTX shares. Leerink Partners initiated coverage on Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, October 15th. UBS Group set a $9.00 price objective on Entera Bio in a report on Friday, September 18th. Wall Street Zen downgraded Entera Bio from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Lifesci Capital assumed coverage on Entera Bio in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.60.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.